Befotertinib
Sponsors
Betta Pharmaceuticals Co., Ltd., Sun Yat-sen University, Fudan University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hebei Medical University Fourth Hospital
Conditions
3-year Disease-free SurvivalAdjuvant Drug TherapyEGFREGFR G719XEGFR L861QEGFR S768ILocally Advanced or Metastatic Non-small Cell Lung Cancer With Previously Untreated EGFR-sensitive Mutations and ECOG Performance Status Score ≥2NSCLC
Phase 2
Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer
Active, not recruitingNCT05007938
Start: 2021-08-12End: 2024-12-31Target: 30Updated: 2024-08-23
Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations
RecruitingNCT06517953
Start: 2024-07-17End: 2027-12-24Target: 23Updated: 2024-07-25
Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC
RecruitingNCT06863506
Start: 2024-10-01End: 2027-12-30Target: 78Updated: 2025-03-07
Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI
RecruitingNCT07181499
Start: 2025-09-30End: 2028-12-31Target: 28Updated: 2025-09-30
ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy
Not yet recruitingNCT07410611
Start: 2026-02-10End: 2030-02-28Target: 84Updated: 2026-02-13
Phase 4
Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients
RecruitingNCT06561620
Start: 2024-05-01End: 2029-05-01Target: 592Updated: 2024-08-22
A Clinical Study Comparing the Efficacy and Safety of Befotertinib Versus Icotinib in Patients With Previously Untreated EGFR-sensitive Mutation-positive Non-small Cell Lung Cancer With ECOG Score ≥2
Not yet recruitingNCT07900243
Start: 2026-11-30End: 2030-12-31Target: 100Updated: 2026-10-28